Kathryn Falberg

Ms Falberg has served as a member of the board since September 2017. Previously, she served as Executive Vice President and CFO of Jazz Pharmaceuticals, a multinational specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and CFO since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications, and information technology. From 1995 to 2001, Ms Falberg was with Amgen, a biotechnology company, where she served as Senior Vice President, Finance and Strategy, and CFO; and prior to that she was Vice President, Chief Accounting Officer, and Treasurer. Ms Falberg currently serves as a member of the Board of Directors for the public biopharmaceutical companies Aimmune Therapeutics, aTyr Pharma, Axovant Sciences and The Trade Desk, and recently served on the Board of Directors of Medivation until its acquisition by Pfizer.